Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial
Titel:
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial
Auteur:
Neal, Joel W Dahlberg, Suzanne E Wakelee, Heather A Aisner, Seena C Bowden, Michaela Huang, Ying Carbone, David P Gerstner, Gregory J Lerner, Rachel E Rubin, Jerome L Owonikoko, Taofeek K Stella, Philip J Steen, Preston D Khalid, Ahmed Ali Ramalingam, Suresh S